Clascoterone Side Effects

Reported Clascoterone side effects

Clascoterone's side effect profile at the approved indication (1% cream twice daily to facial acne) is generally favorable — consistent with its design as a topical antiandrogen with rapid systemic inactivation — with most adverse events being mild application site reactions at rates comparable to vehicle placebo. Serious side effects are rare. The one notable safety consideration is HPA axis suppression observed in pediatric patients during a maximum-use safety study, which is addressed in the FDA labeling and requires monitoring awareness particularly for use in younger children or with large-surface-area application. In the context of topical dermatology, clascoterone has a relatively benign safety profile, substantially better than the systemic side-effect profiles of oral antiandrogens used for similar indications. That said, honest discussion requires coverage of the full spectrum of effects, interactions, and special populations. Application site reactions — the most common side effects. The most frequently reported adverse events in the Phase 3 clinical trials were mild application site reactions, occurring at rates of approximately 2-4% in clascoterone-treated patients, largely comparable to vehicle-treated rates: Application site erythema (redness): ~2-4% of patients; typically mild, transient, and not requiring treatment discontinuation. Often resolves with continued use as the skin adapts. Application site scaling or dryness: ~1-3% of patients; may be modestly improved by moisturizer use after cream application or by reducing application frequency temporarily. Application site pruritus (itching): ~1-2% of patients; mild and usually resolves with continued use. Application site dermatitis or irritant contact dermatitis: rare, but can occur — persistent significant erythema, swelling, or vesiculation at the application site warrants discontinuation and dermatologic evaluation. Application site stinging or burning on application: occasional, typically mild and transient. Management strategies: (1) apply to clean, dry skin (moist skin can increase penetration and irritation); (2) use a fragrance-free, non-comedogenic moisturizer after clascoterone has absorbed (typically 5-10 minutes); (3) consider reducing to once-daily initially if irritation occurs, building up to twice-daily as tolerated; (4) avoid simultaneous application of other potentially irritating topicals (retinoids, benzoyl peroxide at high concentrations, alpha-hydroxy acids) at the same time — space them out (morning/night) or on alternating days; (5) avoid applying to broken or abraded skin; (6) gentle, fragrance-free cleanser rather than harsh scrubs. HPA axis suppression — the boxed-concern reality. This is the most clinically-relevant safety finding for clascoterone and deserves careful discussion. In the pediatric HPA axis safety study (29 patients aged 9-11 with moderate-to-severe facial acne, applying 1% cream twice daily to face and shoulders under maximum-use conditions for 2 weeks), approximately 17% (5/29) demonstrated measurable HPA axis suppression defined by post-ACTH-stimulation cortisol below standard thresholds. Key context: (1) suppression was reversible on discontinuation within 4 weeks; (2) no subject developed clinical adrenal insufficiency during the study; (3) suppression was concentrated in the younger age range with intensive application conditions; (4) suppression has not been widely observed in adolescents or adults under routine clinical use. Mechanism is thought to involve systemic absorption of clascoterone hydrolysis products (particularly cortexolone) at levels sufficient to affect HPA axis function in younger children with still-maturing endocrine systems and thinner skin (greater percutaneous absorption per unit surface area). Clinical implications: (a) FDA labeling specifically cautions about HPA axis suppression risk, particularly in pediatric patients and with large-surface-area or occlusive application; (b) routine HPA axis testing is not mandatory for all patients but should be considered in pediatric patients (especially under 12), patients with extensive body acne requiring large treatment surface area, or patients with prolonged continuous use; (c) signs/symptoms of adrenal insufficiency (fatigue, weight loss, dizziness, hypotension, hyperpigmentation, hyponatremia) warrant evaluation; (d) in general, limit application to the smallest area reasonable, avoid occlusion, and discontinue if HPA axis concerns arise. Signs and symptoms of adrenal insufficiency (to watch for if using clascoterone, especially pediatric or large-surface applications): (1) persistent fatigue; (2) weakness; (3) weight loss or anorexia; (4) nausea, vomiting; (5) orthostatic dizziness or hypotension; (6) hyperpigmentation; (7) salt craving; (8) hypoglycemia symptoms; (9) electrolyte abnormalities (hyponatremia, hyperkalemia). Any of these in the context of clascoterone use warrants discontinuation and medical evaluation. Systemic antiandrogen effects — generally absent at topical doses. Because clascoterone is rapidly hydrolyzed to cortexolone upon systemic absorption, and cortexolone has weak AR binding, systemic antiandrogen effects are not typically observed with routine topical clascoterone use. Specifically: (a) gynecomastia (breast tissue enlargement in men) — not reported as a clascoterone-related event; contrasts sharply with systemic AR antagonists like spironolactone; (b) sexual dysfunction (decreased libido, erectile dysfunction, reduced ejaculate volume) — not reported; contrasts with 5α-reductase inhibitors finasteride and dutasteride; (c) menstrual irregularity in women — not a reported clascoterone effect; contrasts with spironolactone (~20% rate of menstrual irregularity); (d) feminization — not relevant; clascoterone does not have estrogenic activity. This favorable systemic profile is one of clascoterone's main therapeutic differentiators from oral antiandrogens. Electrolyte and renal effects — minimal at therapeutic doses. Unlike spironolactone, which causes hyperkalemia through its mineralocorticoid receptor antagonism, clascoterone has minimal mineralocorticoid-pathway effects at therapeutic doses. Hyperkalemia is not a recognized clascoterone-associated adverse effect. Renal function is not affected by routine topical use. Hormonal / endocrine effects — generally minimal apart from HPA axis consideration. Testosterone levels, DHT levels, estradiol, LH, FSH, cortisol (beyond HPA axis suppression in pediatric maximum-use study), and other endocrine markers are not significantly altered by routine clascoterone topical use based on available pharmacokinetic and clinical data. The compound's systemic footprint is meaningfully small. Photosensitivity — no specific concern. Unlike topical retinoids (tretinoin, adapalene, trifarotene) and some other topical acne agents, clascoterone is not specifically associated with increased photosensitivity. Standard sun protection is reasonable for all acne patients but clascoterone does not specifically mandate increased photoprotection beyond general skin-care best practices. Skin atrophy — not a concern. Clascoterone is not a corticosteroid despite its steroidal chemical scaffold; it does not produce the skin atrophy, telangiectasias, hypopigmentation, or steroid-induced acne that topical corticosteroids can produce. This is an important distinction — patients should not conflate clascoterone with topical corticosteroids or avoid it based on corticosteroid-related concerns. Allergic / hypersensitivity reactions — rare but possible. True hypersensitivity to clascoterone or cream excipients is rare but possible. Signs would include significant persistent erythema, swelling, vesiculation, or wheezing/anaphylaxis (extraordinarily rare with topical application). Discontinuation and evaluation warranted for any suspected hypersensitivity. Drug interactions — generally minimal. Clascoterone has a favorable drug interaction profile given its topical administration and low systemic exposure. Key interactions to consider: Topical acne / skincare regimens: (a) topical retinoids — compatible, commonly combined; (b) benzoyl peroxide — compatible, commonly combined; (c) topical antibiotics (clindamycin, erythromycin) — compatible; (d) topical dapsone — compatible; (e) topical calcineurin inhibitors (tacrolimus, pimecrolimus) — compatible for general dermatology use. (f) alpha-hydroxy acids, beta-hydroxy acids (salicylic acid), retinol — compatible but sequence timing to minimize irritation. Topical corticosteroids: theoretical combined HPA axis suppression concern — if a patient requires concurrent topical corticosteroid therapy for a separate condition, avoid large-surface-area coadministration and consider HPA axis monitoring with prolonged combined use. Systemic AR modulators: (a) spironolactone — compatible for combined use (targeting different body zones with different mechanisms); clinically common in adult women with extensive acne; (b) finasteride / dutasteride — compatible; mechanisms are complementary (5α-reductase inhibition vs AR antagonism); (c) hormonal contraceptives — compatible; no pharmacokinetic interaction; (d) isotretinoin — generally avoided with clascoterone during active isotretinoin course because isotretinoin is a dominant acne treatment making clascoterone redundant; no specific interaction concern. Systemic medications: minimal interaction potential due to low systemic exposure of clascoterone. General rule: clascoterone topical at routine doses has minimal expected impact on other systemic drug pharmacokinetics. Pregnancy — insufficient data, avoid. Clascoterone has not been adequately studied in pregnancy. FDA labeling notes insufficient data; animal studies have not shown reproductive toxicity at clinically relevant doses, but human pregnancy data are minimal. Recommendation: avoid clascoterone during pregnancy; discontinue if pregnancy is confirmed during treatment; alternative acne treatments (azelaic acid, erythromycin topical, gentle cleansing) are preferred in pregnancy. The theoretical concern is that any topical antiandrogen absorbed systemically could theoretically affect male fetal development if exposure is significant; while clascoterone's systemic absorption is low, the precautionary principle applies. Breastfeeding — insufficient data, caution. Whether clascoterone or its metabolites are excreted in human milk is not well-characterized. Recommendation: avoid in breastfeeding when possible; if unavoidable, apply only to small areas away from breast tissue, avoid application immediately before nursing, and discuss with healthcare provider. Many dermatologists prefer alternative topical acne therapies during breastfeeding. Pediatric considerations — the specific monitoring context. Clascoterone is FDA-approved for patients 12+. Use in patients under 12 is off-label. The HPA axis suppression concern is particularly relevant for younger pediatric patients; if used off-label in children under 12 (occasionally considered for severe early-onset acne), HPA axis monitoring is warranted. In adolescents 12-17, routine monitoring is not required but awareness of HPA axis suppression signs is reasonable. Geriatric considerations — not primary population but compatible. Acne is uncommon in geriatric populations, so clascoterone use in elderly patients is limited. No specific geriatric-related safety concerns are known; dosing is standard. Hepatic or renal impairment. Because systemic exposure is minimal with topical use, hepatic and renal impairment do not require specific dosing adjustment. Patients with significant liver or kidney disease can generally use clascoterone at standard dosing. Contact with eyes, mouth, mucous membranes — avoid. Clascoterone is for skin application only. Accidental contact with eyes or mouth requires rinsing with water; ingestion is unlikely to cause significant toxicity given the low systemic bioavailability of topical-formulation cream but warrants monitoring. Skin conditions / concomitant dermatoses: caution with application to broken, abraded, or significantly inflamed skin — percutaneous absorption may be increased; irritant potential may be higher. Avoid application to large open wounds, extensive eczema, or psoriatic plaques. When to stop clascoterone and seek evaluation: Signs of allergic reaction (extensive rash, angioedema, wheezing — extraordinarily rare) Persistent severe application site reactions not responding to typical management Signs/symptoms of adrenal insufficiency (fatigue, weight loss, orthostatic symptoms, etc.) Pregnancy confirmation Inadequate response after 12-16 weeks of consistent use (consider escalation to alternative or combination therapy) Progression of acne despite treatment (consider underlying hormonal or medication-induced causes) Long-term safety — reassurance with ongoing monitoring. The open-label extension study (up to 12 months of treatment) did not identify new adverse event signals beyond the pivotal trials. Post-marketing experience since 2021 has not raised new safety concerns. Long-term clascoterone use beyond 12-24 months has limited specific data but is generally considered safe at routine doses based on the pharmacokinetic profile and accumulated experience. Expected vs concerning: Expected — no side effects, or mild application site reactions (redness, dryness, scaling, mild itching) that resolve or stabilize with continued use; no systemic side effects; gradual acne improvement over 4-12 weeks. Concerning — significant persistent application site irritation, any signs of adrenal insufficiency, allergic reaction features, pregnancy.

When to continue, reduce, or stop Clascoterone

Clascoterone contraindications

Absolute contraindications: Known hypersensitivity to clascoterone or components of the cream/solution formulation (including vehicle excipients, preservatives, or propylene glycol in compounded preparations) — discontinue if rash, swelling, significant redness, or systemic allergic symptoms occur. Pregnancy — clascoterone has not been adequately studied in human pregnancy. FDA labeling notes insufficient data to establish safety. Animal studies have not shown clear reproductive toxicity at clinically relevant doses, but human pregnancy data are minimal. Recommendation: avoid clascoterone during pregnancy. Women of childbearing age who become pregnant during clascoterone treatment should discontinue and inform their physician. For pregnant patients with acne, alternatives with better-established safety profiles include azelaic acid, topical erythromycin, and gentle cleansing; some experts consider topical benzoyl peroxide acceptable. Isotretinoin is absolutely contraindicated in pregnancy (teratogenic); oral tetracyclines are contraindicated after the first trimester. Breastfeeding — whether clascoterone or its metabolites (cortexolone) are excreted in human milk is not well-characterized; systemic exposure from topical use is low but not zero. Recommendation: avoid clascoterone in breastfeeding when possible; if use is necessary, apply only to small areas away from breast tissue, do not apply immediately before nursing, and discuss with healthcare provider. Alternative acne therapies with better-established lactation safety profiles are typically preferred. Pediatric use under 9 years — not studied; no safety or efficacy data; not recommended. Relative contraindications requiring medical guidance: Pediatric use 9-11 years — clascoterone is FDA-approved for 12+; off-label use in 9-11 is sometimes considered for severe early-onset acne but should involve (a) dermatologist involvement; (b) limited treatment surface area; (c) HPA axis monitoring consideration given the pediatric HPA axis study findings; (d) weighing benefits of treatment vs risks of non-treatment (psychosocial impact of severe acne in this age group). Extensive body acne requiring large-surface-area application — the HPA axis suppression concern becomes more relevant with large-surface-area topical application; for patients requiring treatment of face plus shoulders, chest, or back, consider: (a) starting with limited surface area and assessing; (b) avoiding occlusive application; (c) HPA axis monitoring at baseline and periodically; (d) weighing risk-benefit vs alternative therapies (oral antibiotics, isotretinoin). Concurrent systemic or topical corticosteroid use — combining clascoterone (which may produce mild systemic effects on cortisol pathway) with other corticosteroid therapies increases theoretical HPA axis suppression concern. If concurrent corticosteroid use is necessary, monitor accordingly and consider specialty consultation. Broken, abraded, or significantly inflamed skin — avoid application directly to broken skin; percutaneous absorption is increased and irritation potential higher. Allow skin to heal before resuming application. Concurrent isotretinoin therapy — typically not combined; isotretinoin provides dominant acne effect; clascoterone is redundant and may additively increase dryness/irritation. Sequential use (clascoterone before or after isotretinoin course) is reasonable; simultaneous use during isotretinoin is generally avoided. Active cancer treatment — discuss with oncology team. Clascoterone itself is not a chemotherapy or oncologic agent; most oncology teams do not specifically prohibit acne therapy but want awareness of all concurrent medications. For prostate cancer patients receiving systemic antiandrogen therapy (e.g., bicalutamide, enzalutamide, abiraterone), topical clascoterone would be redundant and unnecessary; for other cancer patients with acne (including acneiform eruptions from EGFR inhibitors), consultation with oncology-dermatology is appropriate. History of adrenal insufficiency or HPA axis disorders — use with caution given the HPA axis suppression signal in pediatric studies; consider alternative therapies or monitor HPA axis function during treatment. History of severe allergic reactions to topical skincare products or cosmetics — introduce clascoterone cautiously with small test area initially; stop if reaction develops. Eye area, lips, mucous membranes — do not apply to eyes, mouth, inside nostrils, lips, or mucous membranes; clascoterone is for skin application only. Accidental contact requires rinsing with water. Situations warranting medical consultation before use: Pregnancy, actively planning pregnancy, or pregnancy possibility Breastfeeding Pediatric age under 12 (off-label consideration) Extensive body acne requiring large-surface treatment Known HPA axis or adrenal insufficiency history Active oncologic treatment Severe acne potentially requiring isotretinoin instead Uncertainty about diagnosis (acne vs rosacea vs folliculitis vs perioral dermatitis) Pregnancy testing considerations: For women of childbearing potential prescribed clascoterone for facial acne without concurrent contraception concerns, routine pregnancy testing is not mandated (unlike isotretinoin under iPLEDGE program). However, women should be counseled about pregnancy avoidance during treatment; any missed period or pregnancy concern warrants pregnancy test and discontinuation. Signs and symptoms suggesting need for discontinuation: Severe or persistent application site reactions not responding to typical management (dose reduction, moisturization) Signs of allergic reaction: significant rash beyond application site, angioedema, respiratory symptoms (extraordinarily rare but possible) Symptoms suggesting adrenal insufficiency: persistent fatigue, unexplained weakness, weight loss, orthostatic symptoms, electrolyte abnormalities — evaluate and discontinue if suspicion is substantial Pregnancy confirmation during treatment Inadequate response after 12-16 weeks consistent use — consider alternative or combination therapy Worsening acne despite treatment — reassess diagnosis, adherence, potential underlying contributions Drug interaction considerations for contraindication evaluation: Most prescription medications: compatible with topical clascoterone given low systemic exposure. Other topical antiandrogens (e.g., topical flutamide, topical spironolactone in compounded preparations) — theoretical redundancy; not typically combined. Oral/systemic corticosteroids: theoretical combined HPA axis concern, particularly with prolonged systemic steroid therapy + extensive surface area clascoterone use. Topical corticosteroids: avoid simultaneous application to the same region; use at different times if both needed; consider HPA axis monitoring with prolonged combined use. Legal and regulatory status: Clascoterone (Winlevi brand) is an FDA-approved prescription topical dermatologic agent in the United States, indicated for acne vulgaris in patients 12 years and older. Marketing authorization has been obtained in the European Union, United Kingdom, and various other markets. Not a controlled substance; not scheduled; requires prescription for access. International availability and brand names vary by market; Winlevi is the primary brand in US and North America, marketed by Sun Pharmaceutical under license from Cassiopea. Compounded preparations for off-label use (particularly alopecia) require prescription and are prepared by accredited compounding pharmacies. WADA permits clascoterone for topical use (not a performance-improving substance; not on prohibited list). Post-marketing surveillance: The FDA MedWatch program accepts adverse event reports; patients or clinicians noting unexpected or serious adverse events can report to FDA (1-800-FDA-1088 or online). Post-marketing safety monitoring has not identified new safety concerns beyond the HPA axis suppression finding from the pediatric study and the expected application site reactions. Quality variability — primarily a compounded-preparation concern: Commercial Winlevi is pharmaceutical-grade and highly consistent. Compounded clascoterone preparations can vary in quality depending on compounding pharmacy practices; choose accredited compounding pharmacies with good quality-control records. Not medical advice: This content is educational. Clascoterone use should be under the guidance of a prescribing clinician (dermatologist, primary care, or appropriate specialist). Specific decisions — whether to use clascoterone for acne or off-label hair loss, combination regimen selection, HPA axis monitoring strategy, pregnancy planning — warrant physician involvement tailored to individual circumstances. Clascoterone is a real pharmaceutical with a real evidence base, but it is not a panacea and is not a substitute for complete dermatologic or hair-loss management.

Why vendor quality drives Clascoterone side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Clascoterone side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .